Does TRICARE Cover Rapamycin (Sirolimus)?
A clinical guide to TRICARE coverage, prior authorization, formulary tier, step therapy, and appeal options for rapamycin (sirolimus) in 2025.
Rapamycin
56 source-based articles maintained by the HealthRX.com Editorial Team.
56articles
7topic areas covered
Jul 14, 2025latest review
Rapamycin library
Showing 56 of 56 clinical reviews.
Rapamycin (Sirolimus) Adolescent (12 to 17) Dosing
Evidence-based guide to sirolimus dosing in adolescents aged 12, 17, covering FDA-approved transplant indications, weight-based calculations, trough monitoring, and off-label considerations.
Rapamycin (Sirolimus) Adolescent Monitoring: What Clinicians and Parents Need to Know for Ages 12 to 17
Evidence-based monitoring guide for rapamycin (sirolimus) in adolescents aged 12 to 17, covering trough levels, growth tracking, metabolic labs, immune function, and mental health screening.
Rapamycin (Sirolimus) Adult Dosing for Ages 30 to 49: Evidence-Based Protocols
Complete guide to rapamycin (sirolimus) dosing for adults aged 30 to 49, covering off-label longevity protocols, transplant dosing, monitoring requirements, and safety considerations.
Rapamycin (Sirolimus) After Bariatric Surgery: What Clinicians Need to Know
A clinical deep-dive into sirolimus pharmacokinetics, wound healing risks, mTOR-mediated metabolic effects, and dosing considerations specific to post-bariatric surgery patients.
Rapamycin (Sirolimus) and Sleep Architecture: What the Evidence Actually Shows
A clinical deep-dive into how rapamycin (sirolimus) affects sleep architecture, circadian biology, mTOR signaling in the brain, and what the PEARL trial and related primary literature reveal for patients and prescribers.
Rapamycin (Sirolimus) Appetite & Cravings Changes: What the Evidence Actually Shows
A clinician-level review of how rapamycin (sirolimus) affects appetite, hunger signaling, and food cravings, covering transplant doses, low-dose longevity protocols, mTOR biology, and the PEARL trial data.
Rapamycin (Sirolimus) Autoimmune Disease Considerations
An evidence-based guide to how sirolimus affects autoimmune disease, mechanisms, clinical evidence, dosing considerations, and risks, for clinicians and informed patients.
Rapamycin (Sirolimus) Bone Health and Density Impact
An evidence-audited look at how rapamycin (sirolimus) affects bone remodeling, what transplant-dose data actually show, what is unverified, and how to think about monitoring if you are on the drug for transplant immunosuppression or off-label longevity use.
Rapamycin (Sirolimus) Cancer Risk Signal Review
A physician-level review of the cancer risk data for rapamycin (sirolimus), covering transplant cohorts, mTOR biology, animal data, and what the PEARL trial tells us about off-label longevity use.
Rapamycin (Sirolimus) Cardiovascular Impact: Long-Term Evidence Review
A physician-level review of rapamycin (sirolimus) cardiovascular effects over time, covering atherosclerosis, dyslipidemia, hypertension, cardiac aging, and emerging longevity trial data including PEARL 2024.
Rapamycin (Sirolimus) Cognitive Function Impact: What the Evidence Shows
A deep dive into how rapamycin (sirolimus) affects cognition in humans and animals, covering mTOR biology, clinical trial data including PEARL (2024), dosing, and safety considerations for off-label longevity use.
Rapamycin (Sirolimus) Complete Drug-Drug Interaction Profile
A clinician-grade guide to every major rapamycin (sirolimus) drug-drug interaction, including CYP3A4 inhibitors, inducers, calcineurin inhibitors, and off-label longevity dosing considerations.
Rapamycin (Sirolimus) Compounded vs Branded: A Clinical Comparison
A comparison of compounded sirolimus versus branded Rapamune, covering bioavailability, regulatory status, dosing for off-label longevity use, and what the PEARL trial data show.
Rapamycin (Sirolimus) Cost vs. Alternatives in Class
A clinical comparison of sirolimus pricing against everolimus, metformin, and other mTOR-adjacent longevity compounds, with evidence-based guidance on value per dollar.
Rapamycin (Sirolimus) Dosing for Older Adults (50 to 64): What the Evidence Supports
Evidence-based guide to rapamycin (sirolimus) dosing in older adults aged 50 to 64, covering off-label longevity protocols, FDA-approved transplant doses, safety monitoring, and age-specific considerations.
Rapamycin (Sirolimus) Dosing for Young Adults (18 to 29): What the Evidence Actually Shows
Evidence-based guide to rapamycin (sirolimus) dosing considerations for adults aged 18-29, covering off-label longevity protocols, fertility risks, immune effects, and monitoring requirements.
Rapamycin (Sirolimus) Dosing in Hepatic Impairment
A guide to sirolimus dose adjustments in hepatic impairment, covering PK changes, FDA labeling, clinical monitoring, and emerging longevity-use data.
Rapamycin (Sirolimus) Dosing in Renal Impairment
A guide to sirolimus dosing adjustments, pharmacokinetics, and monitoring in patients with chronic kidney disease, transplant nephropathy, and off-label longevity use.
Rapamycin (Sirolimus) Food & Supplement Interactions: A Clinical Guide
Comprehensive guide to rapamycin (sirolimus) food and supplement interactions, covering grapefruit, St. John's Wort, fat-soluble vitamins, and key pharmacokinetic data with primary-source citations.
Rapamycin (Sirolimus) Future Formulations and Pipeline: What's Coming Next
A clinical deep dive into rapamycin's emerging formulations, next-generation rapalogs, selective mTORC1 inhibitors, and longevity-focused pipeline trials currently in development.
Rapamycin (Sirolimus) Hair and Skin Changes: What Patients and Clinicians Need to Know
What current labels and human studies show about sirolimus acne, rash, wound healing, hair complaints, topical use, and low-dose longevity evidence.
Rapamycin (Sirolimus) Liver Function Impact: What the Clinical Evidence Shows
A deep dive into how rapamycin (sirolimus) affects liver function, including hepatotoxicity risk, transaminase changes, lipid effects, and monitoring protocols backed by primary literature.
Rapamycin (Sirolimus) Manufacturing, Supply & Shortage History
A clinical deep-dive into how sirolimus is manufactured, its supply chain vulnerabilities, FDA shortage records, and what prescribers and patients should know about current availability.
Rapamycin (Sirolimus) Mechanism of Action: Full Pathway Explained
A physician-level breakdown of how rapamycin (sirolimus) works, from FKBP12 binding through mTORC1 inhibition to downstream effects on autophagy, senescence, and immune modulation.
Rapamycin (Sirolimus) Mental Health and Mood Impact: What the Evidence Shows
A clinician-level review of how rapamycin (sirolimus) affects mood, cognition, anxiety, and depression, covering mTOR neuroscience, PEARL trial data, and practical prescribing guidance.
Rapamycin (Sirolimus) Metabolism and Energy Expenditure: What the Evidence Shows
A clinical deep-dive into how rapamycin (sirolimus) alters mTOR signaling, mitochondrial function, glucose metabolism, and energy expenditure, with primary-literature citations for physicians and informed patients.
Rapamycin (Sirolimus) Microdosing Protocols: What the Evidence Actually Shows
A clinician-level review of rapamycin microdosing protocols for longevity, covering PEARL and other primary trials, dosing regimens, pharmacology, safety data, and what board-certified physicians consider before prescribing off-label sirolimus.
Rapamycin (Sirolimus) Missed-Dose Protocol
Evidence-based guidance on what to do when you miss a dose of rapamycin (sirolimus), including timing rules for weekly off-label longevity dosing and daily transplant regimens.
Rapamycin (Sirolimus) Monitoring for Adults Ages 30 to 49
A complete clinical guide to monitoring sirolimus (rapamycin) in adults aged 30-49, covering lab panels, dosing schedules, safety thresholds, and what the PEARL trial and transplant guidelines say about off-label longevity use.
Rapamycin (Sirolimus) Monitoring for Older Adults Ages 50 to 64
A complete clinical guide to rapamycin (sirolimus) monitoring for adults aged 50 to 64, covering trough levels, lab schedules, drug interactions, and age-specific safety considerations backed by trial evidence.
Rapamycin (Sirolimus) Monitoring for Young Adults Ages 18 to 29
A guide to sirolimus blood-level testing, lab monitoring schedules, fertility considerations, and safety checkpoints for healthy adults aged 18 to 29 using rapamycin off-label.
Rapamycin (Sirolimus) Monitoring Schedule: Labs & Exams
Complete rapamycin (sirolimus) monitoring schedule covering blood trough levels, lipid panels, CBC, renal function, glucose, and imaging exams for both transplant and off-label longevity use.
Rapamycin (Sirolimus) Muscle Preservation Strategies: A Clinical Guide
Board-reviewed clinical guide to rapamycin (sirolimus) muscle preservation strategies, covering mTORC1/mTORC2 biology, optimal dosing schedules, resistance training protocols, and nutritional co-interventions backed by primary literature.
Rapamycin (Sirolimus) Off-Label Uses with Evidence Levels
A clinical review of rapamycin (sirolimus) off-label applications, from longevity and immune aging to skin rejuvenation, with evidence grading for each use case.
Rapamycin (Sirolimus) Overdose and Accidental Excess Dose: Recognition, Management, and Recovery
Evidence-based guide to sirolimus overdose recognition, toxicity management, and clinical recovery. Covers accidental excess dosing in transplant and off-label longevity contexts with FDA and PubMed-cited protocols.
Rapamycin (Sirolimus) Patent Field & Generic Timeline
A clinician-grade review of the sirolimus patent history, generic availability, and what the expiration of key patents means for off-label longevity prescribing and cost.
Rapamycin (Sirolimus) Pediatric Dosing for Children Under 12
Evidence-based guide to sirolimus (rapamycin) dosing in children under 12, covering weight-based protocols, therapeutic drug monitoring, off-label indications, and safety considerations.
Rapamycin (Sirolimus) Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion
A clinician-grade review of sirolimus pharmacokinetics covering oral bioavailability, tissue distribution, CYP3A4 metabolism, 62-hour half-life, and dosing implications for transplant and off-label longevity use.
Rapamycin (Sirolimus) Pre-Surgery Hold Window: How Long to Stop Before an Operation
A physician-level guide to the sirolimus pre-surgery hold window: how long to stop rapamycin before an operation, why wound healing and immune suppression demand a specific washout period, and how to restart safely after surgery.
Rapamycin (Sirolimus) Pregnancy & Lactation Safety
A citation-dense guide to sirolimus safety during pregnancy and breastfeeding, covering mechanism, teratogenicity data, transplant guidelines, and off-label longevity use.
Rapamycin (Sirolimus) Rebound Effects When Stopping
What human evidence and current sirolimus labeling show about stopping rapamycin in transplant and off-label longevity settings—and what is still unknown.
Rapamycin (Sirolimus) Regulatory Status: US, EU, Canada, and UK Approvals Explained
A physician-level review of sirolimus regulatory approvals across the US, EU, Canada, and the UK, covering transplant indications, off-label longevity use, and prescribing pathways.
Rapamycin (Sirolimus) Safety for Adults Ages 30 to 49
A guide to the safety profile of rapamycin (sirolimus) in adults aged 30 to 49, covering dose-dependent risks, monitoring protocols, drug interactions, and what the PEARL trial data actually show.
Rapamycin (Sirolimus) Safety in Older Adults (50 to 64): What the Evidence Shows
A guide to rapamycin (sirolimus) safety for adults aged 50 to 64, covering dose protocols, side effects, lab monitoring, drug interactions, and trial data from PEARL and other studies.
Rapamycin (Sirolimus) Seasonal Use Considerations
A clinician-level guide to adjusting sirolimus dosing, lab monitoring, and infection precautions by season, with primary-literature citations and a practical seasonal framework.
Rapamycin (Sirolimus) Self-Injection Technique and How It Works
Rapamycin (sirolimus) is taken orally, not injected. Learn why, how mTOR inhibition drives its longevity and anti-rejection effects, and what the clinical evidence actually shows about dosing, safety, and monitoring.
Rapamycin (Sirolimus) Sexual Function Impact: What the Evidence Actually Shows
A deep dive into how rapamycin (sirolimus) affects sexual function in men and women, covering mTOR biology, clinical trial data, dose-dependent effects, and practical management strategies.
Rapamycin (Sirolimus) Storage, Stability & Shelf Life
Evidence-based guide to storing rapamycin (sirolimus) correctly, including temperature requirements, light sensitivity, compounded formulation stability, and shelf-life data from FDA labeling and pharmacokinetic studies.
Rapamycin (Sirolimus) What to Expect, Week-by-Week First Month
A week-by-week clinical guide to the first month on rapamycin (sirolimus) for longevity use, covering pharmacokinetics, expected effects, common side effects, dosing schedules, and monitoring protocols backed by primary literature.
Rapamycin (Sirolimus): History and Development From Easter Island to Modern Medicine
The complete history of rapamycin (sirolimus), from its 1972 discovery in Easter Island soil to FDA approval and current longevity research. Mechanism of action, key trials, and clinical development timeline.
Rapamycin (Sirolimus): How to Safely Stop
A guide on how to safely discontinue rapamycin (sirolimus), covering tapering protocols, rebound immunosuppression risks, mTOR reactivation, and what to monitor after stopping.
Rapamycin (Sirolimus): Renal Protection or Renal Risk?
A deep dive into sirolimus and kidney health: when mTOR inhibition protects the kidney, when it harms it, and what the latest trials including PEARL 2024 say about safe dosing.
Rapamycin (Sirolimus): Restarting After Acute Illness
A physician-level guide to safely restarting sirolimus after acute illness, covering hold durations, immune recovery markers, dose re-escalation protocols, and the latest evidence from PEARL (2024) and transplant guidelines.
Sirolimus Safety: FDA Boxed Warnings and Low-Dose Risks
Sirolimus has three FDA boxed warnings for infection, cancer, and mortality risk. Low-dose use still causes ulcers, dyslipidemia, and cytopenias.
Switching From or To Rapamycin (Sirolimus): Protocols for mTOR Inhibitor Transitions
Evidence-based protocols for switching between rapamycin (sirolimus) and other mTOR inhibitors or immunosuppressants, including everolimus, tacrolimus, and off-label longevity regimens.